(A) DrugCell uses a modular neural network design that combines conventional artificial neural networks (ANN) with a visible neural network (VNN) to make drug response predictions.
(B) Binary encodings of individual genotypes are processed through a VNN with architecture guided by a hierarchy of cell subsystems, with multiple neurons assigned per subsystem.
(C) Compound chemical structures are processed through an ANN using the Morgan fingerprint as input features.